BioInvent International
38,9
SEK
+0,91 %
BINV
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 investorer følger denne virksomhed
+0,91%
-15,89%
-13,94%
+18,06%
+105,17%
+119,28%
-19,46%
+40,41%
-95,92%
BioInvent International is active in the pharmaceutical industry. The company focuses on the research and development of antibody drugs used in the treatment of cancer. The company has its own development platform and collaborations take place via the company's partners. In the early development phase, the company is working to recreate the disease biology to get indications about the substance's effect on the disease. The head office is located in Lund, Sweden.
Læs mereMarkedsværdi
2,56 mia. SEK
Aktieomsætning
3,44 mio. SEK
Omsætning
71,46 mio.
EBIT %
-517,69 %
P/E
-
Udbytteafkast, %
-
Finanskalender
27.2
2025
Årsrapport '24
29.4
2025
Delårsrapport Q1'25
29.4
2025
Generalforsamling '24
ViserAlle indholdstyper
BioInvent announces first patient enrolled in Phase 1b/2a study of BI-1607 in combination with ipilimumab and KEYTRUDA (pembrolizumab) in patients with unresectable or metastatic melanoma
BioInvent appoints Ashley Robinson as SVP Strategy & Finance to lead US expansion
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools